Overview

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Status:
Completed
Trial end date:
2014-02-12
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Lexicon Pharmaceuticals